Pharmacovigilance as an imperative of modern medicine – experience from Montenegro

WHO. The importance of pharmacovigilance: Safety monitor-ing of medicinal products. 2002. Available from: http://apps.who.int/medicinedocs/pdf/s4893e/s4893e.pdf

Düsing R. Overcoming barriers to effective blood pressure control in patients with hypertension. Curr Med Res Opin 2006; 22(8): 1545−53.

Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharma-covigilance. Available from: http://ec.europa.eu/health/files/eudralex/vol-1/dir_2010_84

/dir_2010_84_en.pdf

Drug Reactions Database. Available from:

http://www.adr- database.com/WhatareADRs.html

Uppsala Monitoring Centre. Available from:

http://www.who-umc.org/ [cited 2014 September 26].

Reporting Trends - Uppsala Monitoring Centre. Available from: http://who-umc.org/DynPage.aspx?id=108476&mn1=7347

&mn2=7252&mn3=7322&mn4=7558

Jelenkovic A. Adverse drug reactions. Belgrade: Hellen J; 2002. (Serbian)

Dukes MN. Mayler's side effects of drugs. Amsterdam: Else-vier; 1996.

Malgarini RB, Pimpinella G. Thrombotic thrombocytopenic purpura induced by ticlopidine: The power of "dear health professional" letters. Ann Pharmacother 2000; 34(3): 404−5.

Safety of Medicines: A Guide to Detecting and Reporting Ad-verse Drug Reactions - Why Health Professionals Need to Take Action: Why pharmacovigilance is needed in every coun-try. Available from: http://apps.who.int/medicinedocs/en/d/Jh2992e/5.html

Qureshi ZP, Seoane-Vazquez E, Rodriguez-Monguio R, Stevenson KB, Szeinbach SL. Market withdrawal of new molecular entities ap-proved in the United States from 1980 to 2009. Pharmacoepi-demiol Drug Saf 2011; 20(7): 772−7.

European Medicines Agency. Human medicines: Short-acting beta-agonists. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Short-acting_beta-agonists/human_

referral_prac_000013.jsp&mid=WC0b01ac05805c516f

European Medicines Agency. PRAC - PRAC: Agendas, minutes and highlights. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/document_listing/document_listing_000353.jsp&mid=WC0b01ac05805a21cf

Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospec-tive studies. JAMA 1998; 279(15): 1200−5.

Chyka PA. How many deaths occur annually from adverse drug reactions in the United States. Am J Med 2000; 109(2): 122−30.

Levy M, Azaz-Livshits T, Sadan B, Shalit M, Geisslinger G, Brune K. Computerized surveillance of adverse drug reactions in hospital: Implementation. Eur J Clin Pharmacol 1999; 54(11): 887−92.

Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: A systematic review and meta-analysis of pro-spective studies. Br J Clin Pharmacol 2001; 52(1): 77−83.

Nelson KM, Talbert RL. Drug-related hospital admissions. Pharmacotherapy 1996; 16(4): 701−7.

Todorovic Z, Prostran MJ, Janković S. Pharmacovigilance In: Pros-tran M, Stanulović M, Marisavljević D, Đurić D, editors. Pharma-ceutical medicine. Vršac: Hemofarm AD; 2009. p. 467−516. (Serbian)

Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 1995; 274(1): 29−34.

Classen DC, Pestotnik SL, Evans RS, Burke JP. Computerized surveillance of adverse drug events in hospital patients. JAMA 1991; 266(20): 2847−51.

Peyriere H, Cassan S, Floutard E, Riviere S, Blayac J, Hillaire-Buys D, et al. Adverse drug events associated with hospital admission. Ann Pharmacother 2003; 37(1): 5−11.

Hallas J, Gram LF, Grodum E, Damsbo N, Brøsen K, Haghfelt T, et al. Drug related admissions to medical wards: A population based survey. Br J Clin Pharmacol 1992; 33(1): 61−8.

Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329(7456): 15−9.

Pushkin R, Frassetto L, Tsourounis C, Segal ES, Kim S. Improving the reporting of adverse drug reactions in the hospital setting. Postgrad Med 2010; 122(6): 154−64.

Dormann H, Muth-Selbach U, Krebs S, Criegee-Rieck M, Tegeder I, Schneider HT, et al. Incidence and costs of adverse drug reac-tions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting. Drug Saf 2000; 22(2): 161−8.

Bates DW, Leape LL, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med 1993; 8(6): 289−94.

Smith CC, Bennett PM, Pearce HM, Harrison PI, Reynolds DJ, Ar-onson JK, et al. Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol 1996; 42(4): 423−9.

Varenhorst C, James S, Erlinge D, Brandt JT, Braun OO, Man M, et al. Genetic variation of CYP2C19 affects both pharmacokinet-ic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery dis-ease. Eur Heart J 2009; 30(14): 1744−52.

Johnson JA, Bootman JL. Drug-related morbidity and mortality: A cost-of-illness model. Arch Intern Med 1995; 155(18): 1949−56.

Hallas J, Harvald B, Gram LF, Grodum E, Brøsen K, Haghfelt T, et al. Drug related hospital admissions: The role of definitions and intensity of data collection, and the possibility of preven-tion. J Intern Med 1990; 228(2): 83−90.

Thürmann PA. Methods and systems to detect adverse drug re-actions in hospitals. Drug Saf 2001; 24(13): 961−8.

Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998; 45(3): 301−8.

Martínez-Mir I, García-López M, Palop V, Ferrer JM, Estañ L, Ru-bio E, et al. A prospective study of adverse drug reactions as a cause of admission to a paediatric hospital. Br J Clin Pharma-col 1996; 42(3): 319−24.

Francis GS. Cardiac complications in the intensive care unit. Clin Chest Med 1999; 20(2): 269−85.

Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003; 289(9): 1107−16.

Gurwitz JH, Field TS, Avorn J, Mccormick D, Jain S, Eckler M, et al. Incidence and preventability of adverse drug events in nurs-ing homes. Am J Med 2000; 109(2): 87−94.

Olivier P, Boulbés O, Tubery M, Lauque D, Montastruc J, Lapeyre-Mestre M. Assessing the feasibility of using an adverse drug re-action preventability scale in clinical practice: A study in a French emergency department. Drug Saf 2002; 25(14): 1035−44.

European Medicine Agency. Setting the scene: new European Un-ion Pharmacovigilance legislation. Vienna, Austria: Agencies of the European Union; 2012.

Regulation – Low of drugs. "Official Register of Montenegro, no 56/2011". Available from: http://www.sluzbenilist.me/PravniAktDetalji.aspx?tag=%7BEB8D380A-167D-4B1B-BFBB-B6593034D628%7D

(Montenegrian)

CALIMS. Letters to health care workers. Available from: https://www.calims.me/ (Montenegrian)

2014. Annual Report - servlet1. Available from: http://www.calims.me/Portal/faces/servlet1?_afrWindowMode=0&putanja=Izvje%C5%A1taj+o+prijavljenim+ne%C5%BEeljenim+dejstvima+za+2014.+godinu.pdf&_afrLoop=16645829555640651&_adf.ctrl-state=tgt7xozzi_38 (Montenegrian)

2013. Annual Report - servlet1. Available from: http://www.calims.me/Portal/faces/servlet1?putanja=Izvjestaj+o+prijavljenim+nezeljenim+dejstvima+za+2013_+godinu.pdf&_afrWindowMode=0&_afrLoop=16733522002965960&_adf.ctrl-state=1d37e0oggc_38 (Montenegrian)

ALIMS. Godisnji Izvestaj NRL. 2013. Available from: http://www.alims.gov.rs/ciril/files/2014/12/NDL-2013.pdf (Montenegrian)

Safety Monitoring of Medicinal Products: Guidelines for Set-ting Up and Running a Pharmacovigilance Centre: 5. Special Issues in Reporting: 5.3 Under-reporting. Available from: http://apps.who.int/medicinedocs/en/d/Jh2934e/6.3.html

2014 Report on adverse drug reactions. Available from: http://www.halmed.hr/pdf/publikacije/Izvjesce_o_nuspojavama_u_2014.pdf (Croatian)

Mugosa S, Bukumiric Z, Kovacevic A, Boskovic A, Protić D, Todorovic Z. Adverse drug reactions in hospitalised cardiac patients: characteristics and risk factors. Vojnosanit Pregl 2015; 72(11): 975−81.